This page shows the latest David Epstein news and features for those working in and with pharma, biotech and healthcare.
Novartis splits pharma unit as Epstein exits. Restructure sees creation of standalone cancer arm Novartis Oncology. ... Novartis has split its pharma business in two, placing all its cancer assets into a separate unit, and announced the departure of
We cautioned that uptake, particularly in the US, would be very slow at the beginning because access would be blocked," said Novartis' pharma chief David Epstein on the firm's ... Epstein pointed to particularly strong take-up in Germany. Having already
Head of Novartis Pharmaceuticals David Epstein said: "Novartis supports patients being empowered to make it easier for them to manage their chronic conditions. “
D chief David Epstein.
Novartis believes that is because formularies in the US often require patients to try an older drug before Cosentyx and - according to the firm's pharma head David Epstein - that means
David Epstein, division head of Novartis, said: “ Novartis is pleased to be so close to bringing this life-changing medicine to people living with ankylosing spondylitis and psoriatic arthritis who are
More from news
Approximately 1 fully matching, plus 43 partially matching documents found.
David Epstein joins Flagship Pioneering as executive partner. He most recently served as CEO of Novartis Pharmaceuticals. ... US-based Flagship Pioneering has appointed former Novartis Pharmaceuticals chief executive David Epstein as its executive partner
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...